Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease

Contributed by: PR Newswire

Tags

Acousia-New-Investor

More Like This

Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial

Dr. Reimar Schlingensiepen (left, CEO of AudioCure Pharma GmbH) and Prof. Hans Rommelspacher (founder and CSO) receive the award in the therapeutics category. (Photo: AudioCure Pharma)

AudioCure Pharma Receives Hearing Technology Innovator Award for its Innovative Compound AC102 for the Treatment of Sudden Hearing Loss

Inner hair cells in the inner ear (picture: Nemes Laszlo/Shutterstock.com)

Sudden Hearing Loss: AudioCure's Novel Compound AC102 Restores Hearing in Preclinical Models, Published in PNAS

EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round

ALSA Ventures launches novel Gene Therapy portfolio company Axovia Therapeutics to treat Ciliopathies

Sequentia Biotech Secures €10million Equity Investment from Seventure Partners and the EIC Fund to Boost Bioinformatic Solutions for clinical, industrial and research applications (Graphic: Sequentia Biotech)

Sequentia Biotech Secures €10million Equity Investment from Seventure Partners and the EIC Fund to Boost Bioinformatic Solutions for Clinical, Industrial and Research Applications

PR Newswire associated0

Heart Failure start-up, Acorai, closes oversubscribed $4m funding round

PR Newswire associated0

Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies